Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377103511> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4377103511 endingPage "907" @default.
- W4377103511 startingPage "901" @default.
- W4377103511 abstract "Purpose: To investigate the efficacy of entecavir plus peginterferon alfa-2a in the treatment of chronic hepatitis B (CHB) patients with different hepatitis B virus (HBV) genotypes resistant to lamivudine (LAM). 
 Methods: 119 LAM-resistant CHB patients treated in Baoshan People's Hospital from May 2018 to May 2020 were selected. All patients received entecavir and peginterferon alfa-2a for 24 months and were scheduled for regular outpatient review and telephone follow-up. Polymerase chain reaction (PCR) was conducted to determine the HBV genotype and HBV-DNA clearance. Alanine aminotransferase (ALT) normalization rate, HBV-DNA clearance rates, and hepatitis B e-antigen (HBeAg) seroconversion rate were determined in CHB patients with different genotypes. Quality of life for all patients was assessed using SF-36 Scale. 
 Results: Five out of 119 patients were lost during follow-up, with a follow-up rate of 95.80 %. Two HBV genotypes were identified, of which 42 (36.8 %) were type B and 72 (63.2 %) type C. At the 6th and 12th month of follow-up, the HBV-DNA clearance rate, ALT normalization rate, and HBeAg seroconversion rate were significantly higher in CHB patients with genotype B than in patients with genotype C (p < 0.05). There were no significant differences between the three rates in the two groups at 18th and 24th month of follow-up (p > 0.05). The quality of life (QOL) of the patients differed between the two groups (p < 0.05). 
 Conclusion: Entecavir plus peginterferon alfa-2a are effective in treating LAM-resistant CHB patients with different genotypes. Genotype B CHB patients are more suitable for this combination protocol." @default.
- W4377103511 created "2023-05-20" @default.
- W4377103511 creator A5047746548 @default.
- W4377103511 creator A5080333702 @default.
- W4377103511 creator A5087605289 @default.
- W4377103511 date "2023-05-11" @default.
- W4377103511 modified "2023-10-16" @default.
- W4377103511 title "Entecavir/peginterferon alfa-2a combination in the treatment of two genotypes of chronic hepatitis B patients with lamivudine resistance" @default.
- W4377103511 doi "https://doi.org/10.4314/tjpr.v22i4.25" @default.
- W4377103511 hasPublicationYear "2023" @default.
- W4377103511 type Work @default.
- W4377103511 citedByCount "0" @default.
- W4377103511 crossrefType "journal-article" @default.
- W4377103511 hasAuthorship W4377103511A5047746548 @default.
- W4377103511 hasAuthorship W4377103511A5080333702 @default.
- W4377103511 hasAuthorship W4377103511A5087605289 @default.
- W4377103511 hasBestOaLocation W43771035111 @default.
- W4377103511 hasConcept C104317684 @default.
- W4377103511 hasConcept C126322002 @default.
- W4377103511 hasConcept C135763542 @default.
- W4377103511 hasConcept C142462285 @default.
- W4377103511 hasConcept C151678543 @default.
- W4377103511 hasConcept C159047783 @default.
- W4377103511 hasConcept C2522874641 @default.
- W4377103511 hasConcept C2775940106 @default.
- W4377103511 hasConcept C2776175608 @default.
- W4377103511 hasConcept C2776235749 @default.
- W4377103511 hasConcept C2777382497 @default.
- W4377103511 hasConcept C2777410769 @default.
- W4377103511 hasConcept C2777451964 @default.
- W4377103511 hasConcept C2777869810 @default.
- W4377103511 hasConcept C2780040827 @default.
- W4377103511 hasConcept C2780593183 @default.
- W4377103511 hasConcept C3020491458 @default.
- W4377103511 hasConcept C55493867 @default.
- W4377103511 hasConcept C71924100 @default.
- W4377103511 hasConcept C86803240 @default.
- W4377103511 hasConcept C90924648 @default.
- W4377103511 hasConceptScore W4377103511C104317684 @default.
- W4377103511 hasConceptScore W4377103511C126322002 @default.
- W4377103511 hasConceptScore W4377103511C135763542 @default.
- W4377103511 hasConceptScore W4377103511C142462285 @default.
- W4377103511 hasConceptScore W4377103511C151678543 @default.
- W4377103511 hasConceptScore W4377103511C159047783 @default.
- W4377103511 hasConceptScore W4377103511C2522874641 @default.
- W4377103511 hasConceptScore W4377103511C2775940106 @default.
- W4377103511 hasConceptScore W4377103511C2776175608 @default.
- W4377103511 hasConceptScore W4377103511C2776235749 @default.
- W4377103511 hasConceptScore W4377103511C2777382497 @default.
- W4377103511 hasConceptScore W4377103511C2777410769 @default.
- W4377103511 hasConceptScore W4377103511C2777451964 @default.
- W4377103511 hasConceptScore W4377103511C2777869810 @default.
- W4377103511 hasConceptScore W4377103511C2780040827 @default.
- W4377103511 hasConceptScore W4377103511C2780593183 @default.
- W4377103511 hasConceptScore W4377103511C3020491458 @default.
- W4377103511 hasConceptScore W4377103511C55493867 @default.
- W4377103511 hasConceptScore W4377103511C71924100 @default.
- W4377103511 hasConceptScore W4377103511C86803240 @default.
- W4377103511 hasConceptScore W4377103511C90924648 @default.
- W4377103511 hasIssue "4" @default.
- W4377103511 hasLocation W43771035111 @default.
- W4377103511 hasOpenAccess W4377103511 @default.
- W4377103511 hasPrimaryLocation W43771035111 @default.
- W4377103511 hasRelatedWork W2001248409 @default.
- W4377103511 hasRelatedWork W2074281474 @default.
- W4377103511 hasRelatedWork W2118714704 @default.
- W4377103511 hasRelatedWork W2364966985 @default.
- W4377103511 hasRelatedWork W2375298745 @default.
- W4377103511 hasRelatedWork W2382309574 @default.
- W4377103511 hasRelatedWork W2405118428 @default.
- W4377103511 hasRelatedWork W2462452453 @default.
- W4377103511 hasRelatedWork W2463274104 @default.
- W4377103511 hasRelatedWork W3030341579 @default.
- W4377103511 hasVolume "22" @default.
- W4377103511 isParatext "false" @default.
- W4377103511 isRetracted "false" @default.
- W4377103511 workType "article" @default.